Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small ...

Master Regulator Blocking Immunotherapy, Paving the Way for a New Lung Cancer Treatment Apr. 9 ... with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations ...

The aim of surgery in stage 2 to 3b NSCLC patients is curative, but between a third and half of them will experience recurrence after surgery and need additional lines of treatment. Keytruda has ...